The influence of different anticoagulants and sample preparation methods on measurement of mCD14 on bovine monocytes and polymorphonuclear neutrophil leukocytes.

Publisher: Biomed Central Country of Publication: England NLM ID: 101462768 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-0500 (Electronic) Linking ISSN: 17560500 NLM ISO Abbreviation: BMC Res Notes Subsets: MEDLINE

Original Publication: London : Biomed Central, 2008.

Anticoagulants/*chemistry ; Heparin/*chemistry ; Lipopolysaccharide Receptors/*analysis ; Monocytes/*chemistry ; Neutrophils/*chemistry ; Specimen Handling/*methods; Animals ; Cattle ; Cell Membrane/chemistry ; Citrates/chemistry ; Edetic Acid/chemistry ; Female ; Flow Cytometry ; Monocytes/cytology ; Neutrophils/cytology ; Sodium Citrate

Background: Membrane-CD14 (mCD14) is expressed on the surface of monocytes, macrophages and polymorphonuclear neutrophil leukocytes (PMN). mCD14 acts as a co-receptor along with Toll like receptor 4 (TLR 4) and MD-2 for the detection of lipopolysaccharide (LPS). However, studies using different sample preparation methods and anticoagulants have reported different levels of mCD14 on the surface of monocytes and neutrophils. In this study, the influence of various anticoagulants and processing methods on measurement of mCD14 on monocytes and neutrophils was examined.
Results: Whole blood samples were collected in vacutainer tubes containing either sodium heparin (HEPARIN), ethylenediaminetetraacetic acid (EDTA) or sodium citrate (CITRATE). mCD14 on neutrophils and monocytes in whole blood samples or isolated cells was measured by the method of flow cytometry using fluorescein isothiocyanate (FITC)-labeled monoclonal antibody. There was a significant difference (p < 0.05) in the mean channel fluorescence intensity (MFI) of mCD14 on neutrophils in whole blood samples anticoagulated with HEPARIN (MFI = 64.77) in comparison with those in whole blood samples anticoagulated with either EDTA (MFI = 38.25) or CITRATE (MFI = 43.7). The MFI of mCD14 on monocytes in whole blood samples anticoagulted with HEPARIN (MFI = 206.90) was significantly higher than the MFI in whole blood samples anticoagulated with EDTA (MFI = 149.37) but similar to that with CITRATE (MFI = 162.55). There was no significant difference in the percentage of whole blood neutrophils or monocytes expressing mCD14 irrespective of type of anticoagulant used. However, MFI of mCD14 on monocytes was about 3.2-folds (HEPARIN), 3.9-folds (EDTA) or 3.7 folds (CITRATE) higher than those on neutrophils. Furthermore, there was no significant difference in mCD14 levels between unprocessed whole blood monocytes and monocytes in peripheral blood mononuclear cell preparation. Conversely, a highly significant difference was observed in mCD14 between unprocessed whole blood neutrophils and isolated neutrophils (p < 0.05).
Conclusion: From these results, it is suggested that sodium heparin should be the preferred anticoagulant for use in the reliable quantification of the surface expression of mCD14. Furthermore, measurement of mCD14 is best carried out in whole blood samples, both for neutrophils and monocytes.

Thromb Haemost. 2007 Aug;98(2):451-6. (PMID: 17721630)
Eur J Immunol. 1986 Dec;16(12):1583-9. (PMID: 3493149)
Vet Res. 2007 Jan-Feb;38(1):95-108. (PMID: 17156740)
J Dairy Sci. 2005 Jan;88(1):211-22. (PMID: 15591384)
MLO Med Lab Obs. 2007 Oct;39(10):16-8, 20; quiz 22-3. (PMID: 18018679)
Cytokine. 2009 Dec;48(3):267-72. (PMID: 19748283)
J Immunol. 1991 Sep 1;147(5):1567-74. (PMID: 1880416)
J Immunol. 2008 Aug 15;181(4):2916-24. (PMID: 18684983)
BMC Genet. 2008 Aug 08;9:50. (PMID: 18691417)
J Immunol. 1988 Jul 15;141(2):547-52. (PMID: 3385210)
J Immunol. 1995 Jan 15;154(2):753-61. (PMID: 7529285)
FASEB J. 2006 Jul;20(9):1345-51. (PMID: 16816109)
J Leukoc Biol. 1997 Jun;61(6):721-8. (PMID: 9201263)
Infect Immun. 2001 Feb;69(2):1002-8. (PMID: 11159996)
Vet Immunol Immunopathol. 2007 Sep 15;119(1-2):123-30. (PMID: 17686528)
Lab Anim. 2001 Apr;35(2):147-52. (PMID: 11315163)
Immunol Today. 1996 Sep;17(9):424-8. (PMID: 8854561)
Vet Immunol Immunopathol. 2007 Jul 15;118(1-2):92-104. (PMID: 17559944)
Immunology. 2011 Jun;133(2):239-45. (PMID: 21426340)
Immunity. 1994 Sep;1(6):509-16. (PMID: 7534618)
J Immunol. 2008 Dec 1;181(11):8120-32. (PMID: 19018005)
Circulation. 2002 May 7;105(18):2166-71. (PMID: 11994250)
Clin Vaccine Immunol. 2006 Jun;13(6):704-7. (PMID: 16760331)
Eur J Immunol. 1995 May;25(5):1436-41. (PMID: 7539760)
Transfus Med. 1999 Jun;9(2):147-54. (PMID: 10354385)
J Leukoc Biol. 2008 Jan;83(1):48-55. (PMID: 17913973)
J Immunol. 1996 Nov 1;157(9):4119-25. (PMID: 8892647)
J Dairy Sci. 2003 Jul;86(7):2382-9. (PMID: 12906056)
J Exp Med. 2000 Jul 17;192(2):193-204. (PMID: 10899906)
Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):e2-3. (PMID: 18094392)
J Exp Med. 1976 Sep 1;144(3):788-809. (PMID: 1085341)

0 (Anticoagulants)
0 (Citrates)
0 (Lipopolysaccharide Receptors)
1Q73Q2JULR (Sodium Citrate)
9005-49-6 (Heparin)
9G34HU7RV0 (Edetic Acid)

Date Created: 20120216 Date Completed: 20130110 Latest Revision: 20211021

20240829

PMC3312831

10.1186/1756-0500-5-93

22333045